Neurotrauma and mesenchymal stem cells treatment: From experimental studies to clinical trials

Ana Maria Blanco Martinez, Camila de Oliveira Goulart, Bruna dos Santos Ramalho, Júlia Teixeira Oliveira, Fernanda Martins Almeida

Ana Maria Blanco Martinez, Camila de Oliveira Goulart, Bruna dos Santos Ramalho, Júlia Teixeira Oliveira, Fernanda Martins Almeida, Laboratory of Neurodegeneration and Repair, Institute of Biomedical Sciences, Health Science Center, 21941-902, Rio de Janeiro, Brazil
Ana Maria Blanco Martinez, Camila de Oliveira Goulart, Bruna dos Santos Ramalho, Fernanda Martins Almeida, Pathology Department, Faculty of Medicine, Federal University of Rio de Janeiro, 21941-902, Rio de Janeiro, Brazil
Fernanda Martins Almeida, Federal University of Rio de Janeiro, Campus Macaé, 27930-560, Rio de Janeiro, Brazil

Author contributions: Martinez AMB and Almeida FM conceived and designed the manuscript; all authors contributed equally to the acquisition and analysis of data and the manuscript writing; Martinez AMB and Almeida FM revised and approved the final version of the manuscript.

Correspondence to: Ana Maria Blanco Martinez, MD, PhD, Laboratory of Neurodegeneration and Repair, Institute of Biomedical Sciences, Health Science Center, bloco F - sala 12, 21941-902, Rio de Janeiro, Brazil. martinez@histo.ufrj.br
Telephone: +55-21-25626431 Fax: +55-21-25626431
Received: October 29, 2013 Revised: February 26, 2014 Accepted: March 11, 2014 Published online: April 26, 2014

Abstract

Mesenchymal stem cell (MSC) therapy has attracted the attention of scientists and clinicians around the world. Basic and pre-clinical experimental studies have highlighted the positive effects of MSC treatment after spinal cord and peripheral nerve injury. These effects are believed to be due to their ability to differentiate into other cell lineages, modulate inflammatory and immunomodulatory responses, reduce cell apoptosis, secrete several neurotrophic factors and respond to tissue injury, among others. There are many pre-clinical studies on MSC treatment for spinal cord injury (SCI) and peripheral nerve injuries. However, the same is not true for clinical trials, particularly those concerned with nerve trauma, indicating the necessity of more well-constructed studies showing the benefits that cell therapy can provide for individuals suffering the consequences of nerve lesions. As for clinical trials for SCI treatment the results obtained so far are not as beneficial as those described in experimental studies. For these reasons basic and pre-clinical studies dealing with MSC therapy should emphasize the standardization of protocols that could be translated to the clinical set with consistent and positive outcomes. This review is based on pre-clinical studies and clinical trials available in the literature from 2010 until now. At the time of writing this article there were 43 and 36 pre-clinical and 19 and 1 clinical trials on injured spinal cord and peripheral nerves, respectively.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

Key words: Neurotrauma; Stem cell therapy; Mesenchymal stem cells; Pre-clinical studies; Clinical trials

Core tip: Basic and pre-clinical studies have highlighted the positive effects of mesenchymal stem cell (MSC) treatment after spinal cord injury (SCI) and nerve trauma. There are many pre-clinical studies on MSC treatment for SCI and nerve injuries. However, the same is not true for clinical trials, particularly those concerned with nerve trauma. As for clinical trials for SCI, the results obtained so far are not as beneficial as those described in experimental studies. For these reasons basic and pre-clinical studies dealing with MSC therapy should emphasize the standardization of protocols that could be translated to the clinical set with consistent and positive outcomes.

Martinez AMB, Goulart CO, Ramalho BS, Oliveira JT, Almeida FM. Neurotrauma and mesenchymal stem cells treatment: From experimental studies to clinical trials. World J Stem
SPINAL CORD LESION: MECHANISMS OF DEGENERATION AND REGENERATION

Spinal cord injury (SCI) causes motor and sensory deficits that impair functional performance, and significantly impacts expectancy and quality of life of affected individuals. The estimated annual global incidence of SCI is 15-40 cases per million inhabitants[1]. In addition to the sensory and functional deficits, spinal cord injury also causes great economic impact on the whole society and it is estimated that this impact is greater than 4 billion dollars per year[2].

SCI results from primary and secondary injury mechanisms. Primary injury refers to the immediate physical injury to the spinal cord as a consequence of laceration, contusion, compression, and contraction of the neural tissue[3]. Pathological changes resulting from primary injury mechanisms include severed axons, direct mechanical damage to cells, and ruptured blood vessels. Secondary injury is responsible for the expansion of the injury site which, in turn, limits the restorative process[4,5]. Specific secondary sequel include alterations in local ionic concentrations, loss of regulation of local and systemic blood pressure, reduced spinal cord blood flow, breakdown of the blood-brain barrier, penetration of serum proteins into the spinal cord, inflammatory responses (alterations in chemokines and cytokines), apoptosis, excitotoxicity, calpain proteases activation, neurotransmitter accumulation, production of free radicals/lipid peroxidation, and imbalance of activated metalloproteinases. These changes lead to demyelination, ischemia, necrosis, and apoptosis of spinal cord parenchyma[6]. These intrinsic responses to tissue injury contribute to an environment that is inhibitory to axonal regrowth[7]. As a consequence of these negative influences when axons in the central nervous system (CNS) are damaged they mount a poor regenerative response.

An injury in the central nervous system generally leads to transection of some nerve fibers as well as damage to the surrounding tissues. The distal ends of the damaged axons form dystrophic growth cones that are exposed to a glial hostile microenvironment. During the initial phase of lesion, inhibitors associated with intact myelin oligodendrocyte and myelin debris, such as NOGO (no go), MAG (myelin associated glycoprotein) and OMGp (oligodendrocyte myelin glycoprotein) proteins can restrict axonal growth[8]. In addition, the recruitment of inflammatory cells and astrocytes, in an attempt to restore the blood-brain barrier, leads to the formation of glial scar, which is usually accompanied by cavities filled with astrocytes secreted substances, such as chondroitin sulfate proteoglycans, which also acts as axon growth inhibitory molecules[9,10]. Furthermore, there is also a lack of trophic factors in the lesion milieu due to intrinsic changes in neurons such as atrophy and death after axonal injury. Together, all these inhibitory molecules form a glial microenvironment which is hostile to axonal repair[11].

Although effective treatments for SCI remain limited, there have been many studies in recent years that have promised for the future from a clinical translational perspective. In general, basic science, preclinical, and clinical studies are aimed at overcoming the factors that are involved in impeding recovery from SCI. Current research is aimed at preventing secondary injury, promoting regeneration, and replacing destroyed spinal cord tissue. In particular, a variety of therapies have been addressed to alter neuro-inflammation[12,13], reduce free radical damage[14,15], reduce excitotoxic damage to neurons[16,17], improve blood flow[18,19], and counteract the effects of local ionic changes[20,21,22]. Current experimental studies and the knowledge of clinical situations provide us with a better understanding of the complex interaction of the pathophysiologic events after SCI. Future approaches should involve strategies aimed at blocking the multiple mechanisms of progressive pathogenesis in SCI and therefore promoting neuroregeneration.

Methylprednisolone (MP), a glucocorticoid, is the only current pharmacotherapy approved for SCI in the human clinic. Although therapy with methylprednisolone has been shown to be protective, its efficacy is limited and it only marginally improves outcomes[23]. Recent advances in SCI research have led to a variety of novel experimental therapeutic strategies. The approach based on cell therapy using various lineages of stem cells has been considered as the most potential for the treatment of spinal cord injuries[24]. Cell transplantation after spinal cord injury has several goals, among them, filling the cavity of the lesion to make a bridge that joins the edges of conserved areas, restore dead cells (neurons or myelinating cells) and make a favorable environment for axonal regeneration. Our laboratory employed in vivo experiments using predifferentiated embryonic stem cells[25], human dental pulp stem cells[26], and mesenchymal stem cell (MSC) (data not published) as a therapy for compressive spinal cord injury in mice, and our results show that these treatments lead to positive and similar functional and morphological responses. Among these lineages, mesenchymal stem cells have strengths such as easy extraction and cultivation, and do not involve ethical and moral issues, making them one of the favorite lineages for spinal cord injury treatment.

MSC THERAPY FOR SPINAL CORD LESION: FROM EXPERIMENTAL STUDIES TO CLINICAL TRIALS

MSC transplantation has been extensively investigated by several groups and these cells can be considered a feasible candidate for treatment of central nervous system diseases because they have characteristics that address the multifactorial events that occur after SCI. These cells have anti-inflammatory, immunomodulatory[27] and neu-
methods of MSC derived from bone marrow or adipose tissue, in another comparative study published in 2012, the authors did not find any difference between animals that received another surgical intervention.

Concerning the paracrine effect, some groups have identified the ability of these cells in secreting pro-survival factors such as insulin-like growth factor (IGF) and transforming growth factor beta (TGF-β). In addition, MSC can be combined with gene therapy, by introducing genes to generate molecules with greater therapeutic potential in promoting neuron survival and regeneration. Table 1 is a summary of preclinical studies using MSC for spinal cord injury, from 2010 until now.

**Sources of MSC**

MSC reside in a range of adult tissues that are easily accessible such as bone marrow, adipose tissue, skin, and even peripheral blood. Most of the studies in SCI use MSC derived from bone marrow and adipose tissue, but it is also possible to get MSC from a perinatal source like umbilical cord blood, umbilical cord matrix, amniotic fluid and placenta. MSC can be extracted from these tissues and plated to be used in autologous transplantation, minimizing the rejection risk.

Studies using MSC extracted from bone marrow in rodents have demonstrated a beneficial effect of cell transplantation after SCI. The beneficial effect of MSC is usually attributed to secretion of neurotrophic factors and anti-inflammatory cytokines. Studies performed with pigs and monkeys showed that MSC can promote axonal growth and sprouting, corroborating the previous results in rodents, thus supporting the clinical use of MSC.

MSC extracted from adipose tissue is considered an attractive source of cells due to easiness of isolation, obtaining of a large amount of cells per donor, and also due to the fact that this tissue is usually discarded after liposuctions. In SCI models, treatment with these cells has resulted in cell survival, neuroprotection, attenuation of secondary damage, axonal regeneration, decrease of gliosis, angiogenesis and enhanced functional recovery. A comparative study using MSC extracted from both bone marrow and adipose tissue after SCI found that both sources of MSC expressed similar surface protein markers, but animals that received adipose tissue cells presented higher levels of tissue BDNF, increased angiogenesis, higher number of preserved axons and a decrease in the number of macrophages, suggesting that the use of MSC extracted from adipose tissue is a better candidate for SCI treatment. However, this is not a consensus and should be further investigated because in another comparative study published in 2012, the authors did not find any difference between animals that received MSC derived from bone marrow or adipose tissue, in terms of axonal regeneration, neuroprotection and functional recovery after a compression lesion in dogs.

Despite being less investigated in terms of SCI treatment, MSC extracted from perinatal tissues also present a therapeutic potential. Human umbilical cord blood cells (hUCBC) transplantation in rats submitted to an injury, resulted in differentiation of these cells into neural cells and downregulation of the fas/caspase-3 pathway in neurons and oligodendrocytes, and also increased levels of anti-apoptotic proteins.

The umbilical cord matrix, also known as Wharton’s jelly, possesses a stem cell population that present some advantages in comparison to other sources because they can proliferate more rapidly and extensively than adult MSC and also because they are easily obtained after normal and cesarean births, with low risk of viral contamination. Other advantage is the possibility of using them for allogenic transplantation because they act by suppressing immune response and are, therefore, considered non-immunogenic. Some studies using umbilical cord matrix-derived MSC indicated that these cells can survive in the injury site and promote repair and recovery after SCI. This improvement is attributed to immunomodulatory and trophic effects through secretion of glial-derived neurotrophic factor (GDNF), BDNF and nerve growth factor (NGF) which are known as supporters of cell survival and regeneration.

The amniotic fluid constitutes another source of MSC, which are obtained from discarded post-partum tissue, without any ethical objections about their use. They present similar proliferation and differentiation patterns in comparison to adult MSC. According to few studies, these cells are able to enhance cell survival and axon myelination and improve hind limb function, after transplantation in SCI models. Some studies have also demonstrated the immunomodulatory effect and trophic support provided by these cells after SCI.

**Issues regarding the quantity and best via of administration of MSC for SCI**

Two important questions that should be addressed when we discuss MSC and its efficacy in treating central nervous system disorders are: the ideal quantity of cells and the best administration. Concerning the cell quantity, the literature presents several studies using different amount of cells. In terms of cell administration, most transplantation is delivered directly into the injury site or adjacent to it, by injecting few microliters of cell suspension. Attempts have been made to inject cells intravenously or intraperitoneally in order to decrease tissue damage and, thus, avoiding subjecting the individual to another surgical intervention.

There are several studies that injected different quantity of cells with similar results. Apart from the difference on the quantity of cells, there are other points that make the comparison among these studies difficult, such as the diversity of lesion models, animal types and route of cell administration. For example, Gzikova and colleagues.
Table 1  Summary of pre-clinical studies using mesenchymal stem cell for spinal cord injury

| Animal | Lesion type       | Cells source                     | Route of administration | Effects on CNS regeneration                                                                 | Ref. |
|--------|-------------------|----------------------------------|-------------------------|------------------------------------------------------------------------------------------------|------|
| Rat    | Contusion         | Human mesenchymal precursor cells| Lesion site             | Improvement in functional recovery and tissue sparing and reduction of cyst volume             | [35] |
| Rat    | Contusion         | Human bone marrow-MSC            | Lesion site, intracisternal, intravenous | Improvement in functional recovery                                                          | [36] |
| Rat    | Hemisection       | Bone marrow-MSC induced into Schwann Cells | Lesion site             | Improvement in locomotor and sensory scores, axonal regeneration and remyelination         | [37] |
| Rat    | Contusion         | Bone marrow-MSC                  | Lesion site, intravenous | Improvement in locomotor scores and NGF expression                                          | [38-40]|
| Rat    | Transection to the dorsal columns and tracts | Bone marrow-MSC, adipose derived-MSC | Lesion site             | Improvement in locomotor scores, increased angiogenesis, preserved axons, decreased numbers of ED1-positive macrophages and reduced lesion cavity formation | [41] |
| Rat    | Hemisection       | Human umbilical cord-derived MSC  | Lesion site             | Suppress mechanical allodynia, and this effect seems to be closely associated with the modulation of spinal cord microglia activity and NRI phosphorylation | [42,43]|
| Rat    | Hemisection       | Human bone marrow-MSC            | Lesion site             | Improvement in locomotor scores, shorter latency of somatosensory-evoked potentials and differentiation into various cells types | [44] |
| Rat    | Hemisection       | Bone marrow-MSC                  | Lesion site             | Improvement in locomotor scores and reduced lesion cavity formation                        | [45] |
| Mouse  | Compression       | Bone marrow-MSC                  | Lesion site             | Improvement in locomotor and sensory scores and reduced lesion volume                      | [46] |
| Rat    | Contusion         | Human bone marrow-MSC            | Lesion site             | Improvement in functional recovery, tissue sparing and reduction in the volume of lesion cavity and in the white matter loss | [35,47-49]|
| Rat    | Contusion         | Human umbilical cord-MSC         | Lesion site             | Improvement in functional recovery, reduction of the extent of astrocytic activation and increased axonal preservation | [50] |
| Dog    | Compression       | Bone marrow, adipose, Wharton’s jelly, umbilical cord derived-MSC | Lesion site             | Improvement in functional recovery, increased numbers of surviving neurons, smaller lesion sizes and fewer microglia and reactive astrocytes in the epicenter of lesion | [51] |
| Rat    | Compression       | Bone marrow-MSC                  | Intravenous             | Improvement in functional recovery, increase of NGF expression, higher tissue sparing and density of blood vessels | [52] |
| Rat    | Contusion         | Human umbilical cord-MSC         | Lesion site             | Improvement in functional recovery, endogenous cell proliferation and oligogenesis, and smaller cavity volume | [53,54]|
| Rat    | Transection       | Human-MSC                        | Lesion site             | Improvement in functional recovery, increased amplitude of motor-evoked potentials, differentiation into neural cells | [55,56]|
| Rat    | Contusion         | Bone marrow-MSC                  | Lesion site             | Improvement in functional recovery, preservation of axons, less scar tissue formation and increase in myelin sparing; higher levels of IL-4 and IL-9 and higher numbers of M2 macrophages, and reduction in TNF-α and IL-6 levels, and in numbers of M1 macrophages | [37-60]|
| Dog    | Compression       | Neural-induced adipose derived-MSC | Lesion site             | Improvement in functional recovery and neuronal regeneration, and reduction of fibrosis | [61] |
| Mouse  | Transection       | Bone marrow-MSC                  | Lesion site             | Improvement in functional recovery and neuronal survival, reduction of cavity volume and attenuation of inflammation, promotion of angiogenesis and reduction of cavity formation | [62-64]|
| Rat    | Compression       | Bone marrow-MSC                  | Lesion site             | Improvement in functional recovery, up-regulation of VEGF mRNA expression, increase in angiogenesis and prevention of tissue atrophy | [65-67]|
| Rat    | Compression       | Human umbilical cord-MSC         | Lesion site             | Improvement in functional recovery, increase in the intensity of 5-HT fibers and in the volume of spared myelination; decrease in the area of the cystic cavity | [68] |
| Dog    | Compression       | Umbilical cord-MSC               | Lesion site             | Improvement in functional recovery, promotion of neuronal regeneration and reduction of fibrosis | [69] |
| Dog    | Compression       | Human umbilical cord-MSC         | Lesion site             | Improvement in functional recovery and remyelination | [70] |
| Rat    | Contusion         | Bone marrow-MSC                  | Intrathecal             | Improvement in functional recovery                                                          | [71] |
| Rat    | Contusion         | Human bone marrow-MSC            | Lesion site, lumbar puncture | Improvement in functional and sensory recovery                                              | [72] |
| Rat    | Contusion         | Neural differentiated and undifferentiated MSC | Lesion site             | Improvement in functional recovery and reduction of cavitation                              | [73] |

CNS: Central nervous system; MSC: Mesenchymal stem cell; TNF: Tumor necrosis factor; IL: Interleukin; NGF: Nerve growth factor; VEGF: Vascular endothelial growth factor.
demonstrated cell survival and enhancement in locomotor performance after MSC transplantation delivered by intravenous injection (one million cells in a volume of 0.5 mL of DMEM) in a model of balloon compressive injury in rats, while Sheth et al. (105) performed cell transplantation (60,000 cells in a volume of 6 µL) directly into the injury site after contusive injury in rats, and also observed an enhancement in locomotor function and a decrease in the lesion volume, indicating a neuroprotective effect of these cells. Thus, it is still difficult to determine the ideal quantity of cells and the best via for stem cell transplantation after SCI. The questions that arise from these studies are: Is there a minimum number of transplanted cells that can be used and yet giving the best results in terms of functional recovery? Can we get similar results with cells injected systemically in comparison to local injection? Studies using the same type of lesion and different amount of cells and administration via should be further undertaken in order to better clarify this issue.

### Time point for cell transplantation

Other crucial issue that should be further addressed here is the time point for cell transplantation after lesion. This is important because the environment created after SCI is hostile for regeneration and can negatively influence cell survival and differentiation. Thus, depending on the time that the treatment is performed the results can be completely different. Most studies have been performed in acute or sub-acute phases, which means immediately or 1-2 wk after injury, respectively (103,105). There are fewer studies in the SCI chronic phase, when cells are delivered in later stages, when the glial scar is already present (106,107).

### Clinical trials

The clinical trials conducted for SCI comprise three different phases with human participation in all phases. The phase 1 trial begins with the administration of the cell transplants to a human subject with the aim to investigate the presence of adverse or toxic effects and treatment safety. People who participate in these trials may experience some risks and have limited benefits. In phase 2, the objective is to determine the potential and variability of a therapy in comparison with a control group. The participants are usually recruited and randomly assigned to the groups (experimental or control) and both, participants and investigators, do not know to which study they have been assigned to. The phase 3 clinical trials are usually the definitive clinical trial. The aim is to confirm the preliminary results obtained at the phase 2, with a statistically significant clinical benefit of the therapeutic intervention. The number of subjects is also larger and multiple study centers are involved (106,107). The majority of the studies using MSC transplantation after spinal cord injury are in phase 1 or 2.

At the time of writing this article there were twenty clinical trials being either completed, ongoing or in the recruitment stage, using either adult or perinatal sources of mesenchymal stem cells in different phases of the disease, and most of them use autologous transplantation to minimize the risk of rejection. Table 2 list the clinical trials listed on the clinical trials.gov.

The number of clinical trials using MSCs for treatment of SCI is increasing, indicating that despite several questions that still need to be addressed at basic and preclinical levels, the MSC are considered potentially beneficial for translational studies.

According to PubMed database, in the last three years only three studies were published in “clinical trials” category, using MSC transplantation after SCI. One of them transplanted autologous bone marrow-derived MSC into the cerebrospinal fluid of patients with complete SCI. The authors described that 45% of the patients showed a recovery, but that there was no difference between these patients and those from control group; they emphasized that despite the fact that results were not positive, the transplantation was a feasible and safe technique, since patients did not present any adverse reaction (108). On the other hand, Park et al. (109) using the same cell source, and repeated cells injections directly into the spinal cord, demonstrated that three of ten patients presented a motor improvement, and significant magnetic resonance changes and electrophysiological results. These results are similar to those obtained by Dai et al. (104) who also demonstrated a clinical improvement in patients that received autologous MSC transplantation. The results of these studies are not conclusive, and, unfortunately, not as good as those obtained in pre-clinical experiments. In spite of that, all of them emphasize mesenchymal stem cell clinical potential.

### WALLERIAN DEGENERATION AND NERVE REGENERATION IN THE PERIPHERAL NERVOUS SYSTEM

Traumatic injury to nerves in the peripheral nervous system (PNS) is a large-scale problem annually affecting more than one million people worldwide. These injuries often result in pain and disabilities, owing to reduction in motor function and sensory perception. Moreover, the trauma can cause emotional, social and work-related disorders, and the affected individuals undergo a reduction in their quality of life (111,112).

While it is widely accepted that the PNS has an inherent potential for regeneration, functional recovery after a lengthy peripheral nerve injury (PNI) remains unsatisfactory (113). After an extensive traumatic nerve injury with a large gap between the proximal and distal nerve stumps, a long period of time is required for regenerating axons to cross that gap. During that time, the ability of axotomized neurons to regenerate declines and Schwann Cells (SC) can no longer support regenerating neurons and their axons. As a result, regenerating axons fail to reach their target organs and the injury cannot be successfully repaired. In order to accelerate the rate of axonal growth many therapeutic strategies are being developed and in-
| Title                                                                 | Lesion type                          | Cells source                        | Phase of the study | Status     | Effects on CNS regeneration                                            |
|----------------------------------------------------------------------|--------------------------------------|-------------------------------------|--------------------|------------|------------------------------------------------------------------------|
| Clinical study of treatment for acute SCI using cultured bone marrow  | Cervical SCI                         | Autologous Bone marrow-MSC          | Terminated         | 1/2        | Rapid and remarkable recovery of ASIA B and C patients, but gradual or  |
| stem cells                                                           |                                      |                                     |                    |            | limited in ASIA A patients.                                            |
| Autologous mesenchymal stem cell in SCI patients                    | Complete cervical or thoracic SCI    | Autologous bone marrow-MSC          | Enrolling by       | 2          | Not informed                                                           |
|                                                                      | Traumatic SCI                        | Umbilical cord derived-MSC          | invitation          |            |                                                                        |
| Different efficacy between rehabilitation therapy and umbilical cord  | Cervical SCI                         | Autologous bone marrow-MSC          | Recruiting         | 3          | Not informed                                                           |
| derived MSCs transplantation in patients with chronic SCI in China   |                                      |                                     |                    |            |                                                                        |
| A phase II/II clinical trial to evaluate the safety and efficacy of  |                                      |                                     | Recruiting         | 1/2        | Not informed                                                           |
| bone marrow-derived MSC transplantation in patients with chronic SCI |                                      |                                     |                    |            |                                                                        |
| Phase 1/II trial of autologous bone marrow derived MSCs to patients  | Traumatic thoracic or lumbar SCI     | Autologous bone marrow-MSC          | Recruiting         | 1/2        | Not informed                                                           |
| with SCI                                                             | Clinical diagnosis of SCI (ASIA A to C)| Autologous Adipose derived-MSC       | Completed           | 1          |                                                                        |
| The effect of intrathecal transplantation of autologous adipose tissue | Clinical diagnosis of SCI             | Autologous Adipose derived-MSC       | Recruiting         | 1          | Not informed                                                           |
| derived MSCs in the patients with SCI, phase I clinical study        |                                      |                                     |                    |            |                                                                        |
| Study the safety and efficacy of bone marrow derived autologous cells | Clinical diagnosis of SCI (ASIA A)   | Autologous bone marrow-MSC          | Active, not recruiting | 1          | Not informed                                                           |
| for the treatment of SCI                                             |                                      |                                     |                    |            |                                                                        |
| Surgical transplantation of autologous bone marrow stem cells with   | Clinical diagnosis of SCI             | Autologous bone marrow-MSC          | Recruiting         | 1/2        | Not informed                                                           |
| glial scar resection for patients of chronic SCI and intra-thecal     | complete spinal cord trans-section    | Autologous bone marrow-MSC          | Completed           | 1/2        |                                                                        |
| injection for acute and subacute injury—a preliminary study          |                                      |                                     |                    |            |                                                                        |
| To study the safety and efficacy of autologous bone marrow stem cells | SCI below C5 (ASIA A to C)           | Autologous bone marrow-MSC          | Recruiting         | 1          | Not informed                                                           |
| in patients with SCI                                                 |                                      |                                     |                    |            |                                                                        |
| Safety of autologous stem cell treatment for SCI in children         | Clinical diagnosis of SCI (ASIA A to D)| Bone marrow-MSC                     | Recruiting         | 1          | Not informed                                                           |
| Autologous bone marrow derived cell transplant in SCI patients       | Traumatic SCI                         | Autologous bone marrow-MSC          | Completed           | 1/2        | Not informed                                                           |
| Phase 1 study of autologous bone marrow stem cell transplantation in  | Traumatic thoracic or lumbar SCI     | Autologous bone marrow-MSC          | Not informed        | 1          | Not informed                                                           |
| patients with SCI                                                    | Traumatic SCI                        | Autologous bone marrow-MSC          | Recruiting         | 1          |                                                                        |
| Administration of autologous stem cells obtained from the bone marrow |                                        |                                     |                    |            |                                                                        |
| Transplant Into Injured Spinal cord: an open-labeled, dose-escalating  | Chronic SCI below C5 and T11 (ASIA A)| Umbilical cord blood mononuclear    | Active, not recruiting | 1/2        | Not informed                                                           |
| trial                                                                  | Clinical diagnosis of SCI             | derived-MSC                         |                    |            |                                                                        |
| Safety and effect of lithium, umbilical cord blood cells and the     | Chronic SCI below C5 and T11 (ASIA A)| Umbilical cord derived-MSC          | Not informed        | 2          |                                                                        |
| combination in the treatment of acute and subacute spinal cord injury|                                        |                                     |                    |            |                                                                        |
| Not informed                                                         |                                        |                                     |                    |            |                                                                        |
| MSC: Mesenchymal stem cell; CNS: Central nervous system; SCI: Spinal  |                                        |                                     |                    |            |                                                                        |
| cord injury.                                                          |                                        |                                     |                    |            |                                                                        |
After an injury the axon is divided into two segments: a proximal stump that remains in contact with the cell body, and a distal stump which is separated from the rest of the neuron. The distal nerve stump undergoes a cascade of events called “Wallerian degeneration”, which is initiated within 24 to 48 h by the entry of calcium in the axoplasm. Calcium influx activates proteases, such as calpains that promote cytoskeletal degradation and disintegration of axoplasm, myelin and axolemma. The rupture of the blood-nerve barrier allows the entry of macrophages into the site of injury and, together with SC, these cells initiate intense phagocytosis and removal of degenerating axon and myelin debris. The barrier permeability decreases two weeks after the injury and then, in the fourth week, increases again in order to regain homeostasis after Wallerian degeneration.

Immediately after injury, the SC in the distal stump of the nerve begin the process of dedifferentiation. Even before axonal degeneration occurs, SC can modify its gene expression and 48 h after injury, they decrease myelin protein expression, acquire a non-myelinating phenotype and begin to express genes related to regeneration, like growth associated protein 43 (GAP-43), neurotrophic factors and their receptors, neuroregulins and their receptors, and assume an intense proliferative activity. About four days after injury SC reach their proliferation peak. These proliferative cells are confined within the tube formed by its own basal lamina and align forming the so called bands of Büngner. These bands columns will form a supportive substrate, providing cues that will guide axon growth toward the target organ, through the release of trophic factors. When SC contact the regenerating axons, the process of re-myelination is started.

The injury also causes a rapid arrival of signals from the damaged axons to the neural body resulting in an extraordinary change from a transmitting to a growth promoting phenotype. Cell body suffers a process called chromatolysis, which is characterized by swelling of the neuronal body and by dispersion of Nissl corpusescles. These changes reflects variations in the metabolic activity of neurons which, as a result, fail to synthesize proteins required for neurotransmission, and start producing substances that are important for axonal sprouting and growth. The regeneration that follows occurs via different mechanisms: the elongation of the distal end of injured axons and the growth of collateral axons from nodes of Ranvier in the proximal stump. However, the success of regeneration and target organ reinnervation depends mostly on the enhancement of the number of regenerating axons, the velocity of axon growth and on the ability of affected neurons to survive and acquire a regenerative phenotype.

In the clinical settings, reconstruction of transected peripheral nerve requires accurate microsurgical repair that connects the proximal and distal stumps of the nerve in a tension-free manner. In cases of injury with tissue loss, autologous peripheral nerve grafts, i.e., autografts, is considered by neurosurgeons the gold standard technique, but unfortunately, even in these cases, the clinical results remain disappointing and, therefore, the search for better strategies is an urgent necessity. In cases of digital nerve lesions, biodegradable artificial nerve conduits are being used in the clinical settings, but their use is still limited to these thin nerves. An advantage of the use of these conduits is that they can be combined with other pro-regenerative strategies, such as the local injection of neurotrophic factors and cells.

New therapeutic approaches should have as a goal an increase of the intrinsic regenerative capacity of transected nerve fibers and a decrease of the extrinsic factors that limit regeneration of severed nerve fibers, thus creating an appropriate environment in which, axon elongation, remyelination and proper reinnervation of target organ may occur. A stem cell-based therapy represents an important new strategy to manage peripheral nerve injury. In the next part of this review we will discuss the potential use of mesenchymal stem cells, in promoting nerve regeneration.

**MSC THERAPY IN PNS: FROM EXPERIMENTAL STUDIES TO CLINICAL TRIALS**

A number of experimental studies have shown the potential of MSC to improve peripheral nerve regeneration following traumatic injuries. These cells may act on nerve regeneration mainly by paracrine, neuro/axonoprotective, or immunomodulatory effects; by transdifferentiation into SCs; by cell-to-cell contact; or even by a combination of the above mechanisms. However, most of the beneficial effects exerted by the MSC are strongly correlated with the production of neurotrophic substances, such as FGF, NGF, ciliary neurotrophic factor, BDNF, GDNF among others.

Our group showed the presence of high levels of NGF-b in the in MSC, in vitro suggesting that they are also able to express this potent neurotrophic factor in vitro; this result could represent one mean by which these cells acted on the enhancement of axon regeneration and remyelination, consequently contributing to the observed return of motor function. In agreement with these findings, bone marrow-MSC locally injected in the mouse sciatic nerve resulted in improvement of regeneration of sensory and motor axons. Because these authors also observed that these cells were capable of increasing neurite outgrowth in vitro through NGF releasing, and that they presented low potential to differentiate into SC...
**in vivo**, they suggested that the beneficial effects exerted by the implanted cells were mainly dependent on their trophic activity rather than their stemness potential\(^\text{[134]}\). In another work, our group also observed the benefits of bone marrow-MSC locally injected in the mouse median nerve following transection and conduit repair. This cell system was capable of increasing the number of both myelinated and unmyelinated fibers, preventing the muscle atrophy and, most importantly, improving functional performance\(^\text{[130]}\).

It is also possible that MSC can act indirectly on nerve regeneration by modulating cellular behaviors such as inducing SC to survive, proliferate, produce neurotrophic factors and promote remyelination. A coculture system with rat bone marrow-MSC conditioned media and SC demonstrated cell-cell interactions despite no direct contact between the two population of cells. MSC not only favored survival and proliferation of SC but also induced them to express NGF, BDNF and NGF receptors\(^\text{[138]}\). This is an important MSC feature as it might indicates that MSC can relay and magnify neurotrophic function from stem cells to glia cells, thus improving peripheral nerve regeneration.

Besides rodents, larger animal models have also been used to investigate the effects of MSC-based therapy on more challenging nerve gaps. Few authors have shown the successful bridging of a 30 mm-long ischiatic nerve defect by means of a biodegradable conduit in dogs\(^\text{[139]}\). After six months of MSC implantation, they observed the reconstruction of ischiatic nerve trunk with restoration of nerve continuity, functional recovery for conducing electrical impulses and transporting materials, and muscle re-innervation, which lead to improvement of locomotion activities. Even more challenging, using a two-fold nerve gap in a similar experimental model but with addition of autologous MSC, the same group\(^\text{[140]}\) demonstrated that the cellular treatment improved nerve regeneration and functional recovery in a manner comparable to the autograft-treated animals, which is considered by neurosurgeons the current gold standard for peripheral nerve repair.

As aforementioned, the great majority of the experimental studies of mesenchymal stem cell-based therapy on the peripheral nerve regeneration use rodents (mainly mice and rats) as animal models\(^\text{[130,133,134,138]}\), perhaps because they are small mammals and, consequently, easy to handle; also, they have been extensively used in the field of genetic engineering for a diversity of experimental trials of gain and loss of function as well as reporter assays. However, there are few studies using non-human primates such as cynomolgus and rhesus monkeys, which share high level of sequence homology with human genome, that have confirmed the feasibility of this cell system for improving nerve regeneration after severe nerve lesions. MSC transplantation into either allogeneic nerve grafts\(^\text{[141]}\) or artificial conduits\(^\text{[142]}\) for bridging severe upper extremity nerve defects in higher primates yielded structurally and functionally regenerated nerves; these studies proved to be safe and effective, thus giving great insight into the use of MSC in human clinics.

MSC obtained from human subjects have also been used in pre-clinical studies for promoting nerve regeneration, yielding promising results\(^\text{[143-145]}\). These studies are of great relevance because they address human MSC properties, clarifying their mechanisms of action, and also provide insight into their effects on peripheral nervous tissue recovery. Interestingly, the authors of these studies demonstrated that human MSC-based therapy improved peripheral nerve regeneration as well as functional recovery. However, McGrath \textit{et al}\(^\text{[45]}\) showed that MSC survived in the conduit and enhanced axonal regeneration only when transplantation was combined with the immunosuppressive treatment, cyclosporine A. As these results provide evidence of the nerve regeneration potential of human MSC, and taking into account that one of the great advantages of MSC is the possibility of auto transplantation without donor-site morbidity, they might encourage the use of this cell system for treating human peripheral nerve trauma.

Thus, the results of pre-clinical studies highlighting the improved outcomes yielded by using MSC with the aim to repair a large nerve gap may increase the feasibility of translation of MSC-based therapy to clinical trials for peripheral nerve applications.

Table 3 summarizes the studies using MSC for nerve injuries, either in pre-clinical or clinical trials, since 2010 until now. To date, only one clinical trial has used autologous bone marrow mononuclear cells within silicone tubes to repair human median or ulnar nerves\(^\text{[46]}\). In this study scores for motor function, sensation and the effect of pain on function were better than those obtained from individuals that had the tubular nerve repair only; However, a possible limitation in this study is the fact that there was a difference between groups regarding the age of individuals and the length of follow-up after treatment, which could represent biases in this study. So, the interval between injury and treatment was always longer than 75 d, which could possibly limit the positive effects exerted by the cells on the nerve regeneration process. Another possible disadvantage of this work is that nerve conduits were made of silicone, a non-biodegradable material, thus requiring a second surgery to remove the conduit. In spite of these limitations cells-treated patients presented a better recovery compared to the untreated. The results of this study will, hopefully, encourage subsequent clinical studies to be conducted safely, with fewer biases, and with the association of the cellular treatment with suitable biodegradable conduits, thus preventing discomfort and complications generated from the use of silicone material.

Although important advances have been achieved in the use of stem cells for improving nerve regeneration, they are still limited to basic and pre-clinical trials. In addition, there are several variables among these studies, such as tissue source; methods of cell isolation, expansion and characterization; route of cell delivery; number
of transplanted cells; therapeutic time window; animal and nerve models; type of injury; number of transplanted cells; and immunogenicity. These variables represent an important obstacle for comparing and contrasting study outcomes from different groups, thus hindering progress in the field.

In 2006, The International Society for Cellular Therapy proposed the development of a set of minimal criteria (adherence to plastic in standard culture conditions, expression of a number of markers and multipotent differentiation potential into osteoblasts, adipocytes and chondroblasts) for defining the MSC for research purposes. Although this action represented a great attempt to allow for comparison of scientific studies among different groups, the criteria for mesenchymal cells from different species should be further considered and well-defined, in particular the non-human and human primate MSC.

**CONCLUSION**

Pre-clinical studies have shown the beneficial effects of MSC therapy in the neurotrauma field. Unfortunately, these effects are not usually seen in the clinical trials, and the results are far from being as good as those described in experimental studies. Therefore, there is an urgent need to seek for standardization of protocols in terms of source of cells, culture conditions, time of treatment after injury, number and via of administration of cells, plasticity and capability of human MSC after extraction and expansion in culture, among other concerns. Basic and pre-clinical studies focusing on these important points will, hopefully, be of great help in terms of their successful implementation in clinical trials.

**REFERENCES**

1. Vawda R, Fehlings MG. Mesenchymal cells in the treatment of spinal cord injury: current &amp; future perspectives. *Curr Stem Cell Res Ther* 2013; 8: 25-38 [PMID: 23270635 DOI: 10.2174/1574888X13080100005]
2. Varma AK, Das A, Wallace G, Barry J, Vertegel AA, Ray SK, Banik NL. Spinal cord injury: a review of current therapy, future treatments, and basic science frontiers. *Neurochem Res* 2013; 38: 895-905 [PMID: 23462880 DOI: 10.1007/s11064-013-0991-6]
3. Jellinger KA. Neurochemical aspects of neurotraumatic and neurodegenerative diseases. *Eur J Neurol* 2011; 18: e104-e104 [DOI: 10.1111/j.1468-1331.2010.03302.x]
4. Yiu G, He Z. Gilai inhibition of CNS axon regeneration. *Nat Rev Neurosci* 2006; 7: 617-627 [PMID: 16859390 DOI: 10.1038/nrv1956]
5. Dumont RJ, Okonkwo DO, Verma S, Hurlbert RJ, Boulous PT, Ellegala DB, Dumont AS. Acute spinal cord injury, part I: pathophysiologic mechanisms. *Clin Neuropharmacol* 2001; 24: 254-264 [PMID: 11586110]
6. Ramer MS, Harper GP, Bradbury EJ. Progress in spinal cord research - a refined strategy for the International Spinal Research Trust. *Spinal Cord* 2000; 38: 449-472 [PMID: 10962607]
7. McKerracher L, David S, Jackson DL., Kottis V, Dunn RJ, Braun PE. Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth. *Neuron* 1994; 13: 805-811 [PMID: 7524558 DOI: 10.1016/0896-6273(94)90247-X]
8. Zuo J, Neubauer D, Dyess K, Ferguson TA, Muir D. Degradation of chondroitin sulfate proteoglycan enhances the neurite-promoting potential of spinal cord tissue. *Exp Neurol* 1998; 154: 654-662 [PMID: 9878200 DOI: 10.1006/exnr.1998.6951]
9. Bradbury EJ, Moon LD, Popat RJ, King VR, Bennett GS, Patel PN, Fawcett JW, McMahon SB. Chondroitinase ABC promotes functional recovery after spinal cord injury. *Nature* 2002; 416: 636-640 [PMID: 11948352 DOI: 10.1038/416636a]
10. Kamada T, Koda M, Dezawa M, Yoshinaga K, Hashimoto M, Koshizuka S, Nishio Y, Moriya H, Yamazaki M. Transplantation of bone marrow stromal cell-derived Schwann cells...
promotes axonal regeneration and functional recovery after complete transection of adult rat spinal cord. J Neuropathol Exp Neurol 2005; 64: 37-45 [PMID: 15715083]

11 Wright KT, El Masri W, Osman A, Choudhury J, Johnson WE. Commentary: Bone marrow for the treatment of spinal cord injury: mechanisms and clinical applications. Stem Cells 2011; 29: 169-178 [PMID: 21732476]

12 Wingrave JM, Schaecher KE, Sribnick EA, Wilford GG, Ray SK, Hazen-Martin DJ, Hogan EL, Banik NL. Early induction of secondary injury factors causing activation of calpain and mitochondria-mediated neuronal apoptosis following spinal cord injury in rats. J Neurosci Res 2003; 73: 95-104 [PMID: 12815713 DOI: 10.1002/pr.10697]

13 Das A, Smith JA, Gibson C, Varma AK, Ray SK, Banik NL. Estrogen receptor agonists and estrogen attenuate TNF-α-induced apoptosis in VSC4.1 motorneurons. J Endocrinol 2011; 208: 171-182 [PMID: 21608701 DOI: 10.1677/JOE-10-0338]

14 Bracken MB. Steroids for acute spinal cord injury. Cochrane Database Syst Rev 2012; 1: CD001046 [PMID: 22258943 DOI: 10.1002/14651858.CD001046.pub2]

15 Samantaray S, Sribnick EA, Das A, Knarayan VH, Matzelle DD, Yalla pragada AV, Reiter RJ, Ray SK, Banik NL. Melatonin attenuates calpain upregulation, axonal damage and neuronal death in spinal cord injury in rats. J Pineal Res 2008; 44: 348-357 [PMID: 18086148 DOI: 10.1111/j.1600-079X.2007.00534.x]

16 Bains M, Hall ED. Antioxidant therapies in traumatic brain and spinal cord injury. Biochim Biophys Acta 2012; 1822: 265-274 [PMID: 22989767 DOI: 10.1016/j.bbapap.2011.10.017]

17 Robert AA, Zamzami M, Sam AE, Al Jaid M, Al Mubarak S. The efficacy of antioxidants in functional recovery of spinal cord injured rats: an experimental study. Neurol Sci 2012; 33: 785-791 [PMID: 22068217 DOI: 10.1007/s10072-011-0829-4]

18 Mazzone GL, Nistri A. Delayed neuroprotection by tiluzole against excitotoxic damage evoked by kainate on rat organotypic spinal cord cultures. Neuroscience 2011; 190: 318-327 [PMID: 21689734 DOI: 10.1016/j.neuroscience.2011.06.013]

19 Rong W, Wang J, Liu X, Jiang L, Wei F, Zhou H, Han X, Liu Z. 17β-estradiol attenuates neural cell apoptosis through inhibition of JNK phosphorylation in SCI rats and excitotoxicity induced by glutamate in vitro. Int J Neurosci 2012; 122: 381-387 [PMID: 22049452 DOI: 10.3109/00207454.2012.686728]

20 Ritz MF, Graumann U, Gutierrez B, Hausmann O. Traumatic spinal cord injury alters angiogenic factors and TGF-beta that may affect vascular recovery. Curr Neurovasc Res 2010; 7: 291-310 [PMID: 20866549 DOI: 10.2174/157015910793358204]

21 Lutton C, Young YW, Williams R, Meedeniya AC, Mackay-Reid J, Liu HJ, Deliot E, Navarro X. Neuroprotection and axonal regeneration after lumbar ventral root avulsion by re-implantation and mesenchymal stem cells transplant combined therapy. Neurotherapeutics 2013; 10: 354-368 [PMID: 23440700 DOI: 10.1007/s11064-013-0178-5]

22 Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove CJ, Bovenkerk JE, Peli CL, Johnstone BH, Considine RV, March KL. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004; 109: 1292-1298 [PMID: 14995132 DOI: 10.1161/01.NE.0000121425.4696.F1]

23 Nakagami H, Maeda K, Morishita R, Iguchi S, Nishikawa Reier PJ. Estrogen receptor agonists and estrogen attenuate TNF-α-induced apoptosis and functional recovery of spinal cord tissues in rats. J Pineal Res 2003; 34: 115-122 [PMID: 12993122 DOI: 10.1111/j.1600-079X.2002.00537.x]

24 Wei X, Du Z, Zhao L, Feng D, Wei G, He Y, Tan J, Lee WH, Hampel H, Dodel R, Johnstone BH, March KL, Farlow MR, Du Y. IFATS collection: The conditioned media of adipose stromal cells protect against hypoxia-ischemia-induced brain damage in neonatal rats. Stem Cells 2009; 27: 478-488 [PMID: 19023052 DOI: 10.1634/stemcells.2008-0333]

25 Azari MF, Mathias L, Ottukz E, Cramp DS, Boyd RL, Petrosa S. Mesenchymal stem cells transplantation and spinal cord injury. Curr Neurovasc Res 2010; 8: 316-323 [PMID: 21629440 DOI: 10.2174/157015910793358204]

26 Hudgotts SI, Simmons PJ, Plant JW. A comparison of the functional outcomes after functional and histological outcomes after mesenchymal stem cells transplantation and spinal cord injury models following treatment with human mesenchymal precursor cell transplantation and recombinant decorin. Exp Neurol 2013; 248: 343-359 [PMID: 23867131 DOI: 10.1016/j.expneurol.2013.06.018]

27 Shin DA, Kim JM, Kim HI, Yi S, Ha Y, Yoon do H, Kim KN. Comparison of functional and histological outcomes after intrascleral, intracisternal, and intravenous transplantation of human bone marrow-derived mesenchymal stromal cells in a rat model of spinal cord injury. Acta Neurochir (Wien) 2013; 155: 1943-1950 [PMID: 23821338 DOI: 10.1007/s00701-013-1799-5]

28 Zamyazi A, Shokrgozar MA, Sadeghi Y, Noroozian M, Heidari MH, Piryaei A. Mesenchymal stem cells as an alternative for Schwann cells in rat spinal cord injury. Iran Biomed 2013; 17: 113-122 [PMID: 23748888 DOI: 10.6091/ib.1121.2013]

29 Kim JW, Ha KY, Molon NJ, Kim YH. Bone marrow-derived mesenchymal stem cell transplantation for chronic spinal cord injury in rats: comparative study between intrascleral and intravenous transplantation. Spine (Phila Pa 1976)
Kang ES, Ha KY, Kim YH. Fate of transplanted bone marrow derived mesenchymal stem cells following spinal cord injury in rats by transplantation routes. J Korean Med Sci 2012; 27: 586-593 [PMID: 22690088 DOI: 10.3346/jkms.2012.27.6.586]

Osaka M, Honmou O, Murakami T, Nonaka T, Houkin K, Hamada H, Kocsis JD. Intravenous administration of mesenchymal stem cells derived from bone marrow after contusive spinal cord injury improves functional outcome. Brain Res 2010; 1343: 226-235 [PMID: 20470799 DOI: 10.1016/j.brainres.2010.05.011]

Zhou Z, Chen Y, Zhang H, Min S, Yu B, He B, Jin A. Comparison of mesenchymal stromal cells from human bone marrow and adipose tissue for the treatment of spinal cord injury. Cytotherapy 2013; 15: 434-448 [PMID: 23376106 DOI: 10.1016/j.jcyt.2012.11.015]

Schira J, Gasis M, Estrada V, Hendricks M, Schmitz C, Trapp T, Kruse F, Kögerl W, Wernet P, Hartung HP, Müller HW. Significant clinical, neuropathological and behavioural recovery from acute spinal cord trauma by transplantation of a well-defined somatic stem cell from human umbilical cord blood. Brain 2012; 135: 431-446 [PMID: 21903726 DOI: 10.1093/brain/awr222]

Roh DH, Seo MS, Choi HS, Park SB, Han HJ, Beitz AJ, Kang KS, Lee JH. Transplantation of human umbilical cord blood or amniotic epithelial stem cells alleviates mechanical allodynia after spinal cord injury in rats. Cell Transplant 2013; 22: 1577-1590 [PMID: 23294734 DOI: 10.3727/096368912X659007]

Choi JS, Leem JW, Lee KH, Kim SS, Suh-Kim H, Jung SJ, Kim UJ, Lee BH. Effects of human mesenchymal stem cell transplantation combined with polymer on functional recovery following spinal cord hemisection in rats. Koran J Pharmacol Pharmacol 2012; 16: 405-411 [PMID: 23269903 DOI: 10.4196/kjp.2012.16.6.405]

Wei X, Wen Y, Zhang T, Li H. Effects of bone marrow mesenchymal stem cells with acellular muscle bio scaffolds on repair of acute hemicranial spinal cord injury in rats. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2012; 26: 1362-1367 [PMID: 23203674]

Boido M, Garbossa D, Fontanella M, Ducati A, Vercelli A. Mesenchymal stem cell transplantation reduces glial cyst and improves functional outcome after spinal cord compression. World Neurosurg 2014; 81: 183-190 [PMID: 23022648 DOI: 10.1016/j.wneu.2012.08.014]

Fang KM, Chen JK, Hung SC, Chen MC, Wu YT, Wu TJ, Lin HI, Chen CH, Cheng H, Yang CS, Tseng SF. Effects of combinatorial treatment with pituitary adenylate cyclase activating peptide and human mesenchymal stem cells on spinal cord tissue repair. PLoS One 2010; 5: e15299 [PMID: 21187995 DOI: 10.1371/journal.pone.0015299]

Park WB, Kim SY, Lee SH, Park JS, Hyun JK. The effect of mesenchymal stem cell transplantation on the recovery of bladder and hindlimb function after spinal cord contusion in rats. BMC Neurosci 2010; 11: 119 [PMID: 20846445 DOI: 10.1186/1471-2202-11-119]

Alexian AR, Kwok WM, Pravid D, Maiman DJ, Fehlings MG. Survival of neurally induced mesenchymal cells may determine degree of motor recovery in injured spinal cord rats. Restor Neurol Neurosci 2010; 28: 761-767 [PMID: 21209491 DOI: 10.3233/RNN-2010-0547]

Gu W, Zhang F, Xue Q, Ma Z, Lu P, Yu B. Transplantation of bone marrow mesenchymal stem cells reduces lesion volume and induces axonal regrowth of injured spinal cord. Neuroplastology 2010; 30: 205-217 [PMID: 19845866 DOI: 10.1111/j.1440-1789.2009.01063.x]

Park SS, Lee YJ, Lee SH, Lee D, Choi K, Kim WH, Kweon OK, Han HJ. Functional recovery after spinal cord injury in dogs treated with a combination of Matrigel and neural induced adipose-derived mesenchymal Stem Cells. Cytotherapy 2012; 14: 584-597 [PMID: 22348702 DOI: 10.1016/j.cyto.2011.07.007]

Zhang W, Yan Q, Zeng YS, Zhang XB, Xiong Y, Wang JM, Chen SJ, Li Y, Bruce IC, Wu W. Implantation of adult bone marrow-derived mesenchymal stem cells transfected with the neurotrophin-3 gene and pretreated with retinoic acid in completely transected spinal cord. Brain Res 2010; 1359: 256-271 [PMID: 20816761 DOI: 10.1016/j.brainres.2010.08.072]

Zeng X, Zeng YS, Ma YH, Lu LY, Du BL, Zhang W, Li Y, Chan WY. Bone marrow mesenchymal stem cells in a three-dimensional gelatin sponge scaffold attenuate inflammation, promote angiogenesis, and reduce cavity formation in exper-
lial cells and neural stem cells promotes functional recovery after spinal cord injury in the rat. Cell Mol Neurobiol 2006; 26: 1167-1180 [DOI: 10.1007/s10571-006-9093-1]

Sheth RN, Manzano G, Li X, Levi AD. Transplantation of human bone marrow-derived spinal cord cells into the contused spinal cord of nude rats. J Neurosurg Spine 2008; 8: 153-162 [PMID: 18248287 DOI: 10.3171/SPI/2008/8/2.153]

Lammertse D, Tuszynski MH, Steeves JD, Curt A, Fawcett JW, Rask C, Ditunno JF, Fehlings MG, Guest JD, Kleitman N, Blight AR, Dobkin BH, Grossman R, Katoh H, Privat A, Kalichman M. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: clinical trial design. Spinal Cord 2007; 45: 232-242 [PMID: 17179970 DOI: 10.1038/sj.sc.3102008]

Steeves JD, Lammertse D, Curt A, Fawcett JW, Tuszynski MH, Ditunno JF, Ellaway PH, Fehlings MG, Guest JD, Kleitman N, Bartlett PF, Blight AR, Dietz V, Dobkin BH, Grossman R, Short D, Nakamura M, Coleman WP, Caviria M, Privat A. Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures. Spinal Cord 2007; 45: 206-221 [PMID: 17179972 DOI: 10.1038/sj.sc.3102008]

Karamouzian S, Nematoollahi-Mahani SN, Nakkah E, Eskandary H. Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients. Clin Neuropathol 2012; 114: 935-939 [PMID: 22644334 DOI: 10.1007/j.clineneuro.2012.02.003]

Park JH, Kim DY, Sung IY, Choi GH, Jeon MH, Kim KK, Jeon SR. Long-term results of spinal cord injury therapy using mesenchymal stem cells derived from bone marrow in humans. Neurosurgery 2012; 70: 1238-147; discussion 1247 [PMID: 22127044 DOI: 10.1227/NEU.0b013e3182438799]

Dai G, Liu X, Zhang Z, Yang Z, Dai Y, Xu R. Transplantation of autologous bone marrow mesenchymal stem cells in the treatment of complete and chronic cervical spinal cord injury. Brain Res 2013; 1533: 73-79 [PMID: 23948102 DOI: 10.1016/j.braine.2013.08.016]

Noble J, Munro CA, Prasad VS, Midra K. Analysis of upper and lower extremity peripheral nerve injuries in a population of patients with multiple injuries. J Trauma 1998; 45: 116-122 [PMID: 9600223]

Robinson LR. Traumatic injury to peripheral nerves. Muscle Nerve 2000; 23: 863-873 [PMID: 10842261 DOI: 10.1002/ten.320]

Huang JH, Cullen DK, Browne KD, Groff R, Zhang J, Pfister B, Zager EL, Smith DH. Long-term survival and integration of transplanted engineered nervous tissue constructs promotes peripheral nerve regeneration. Tissue Eng Part A 2009; 15: 1677-1685 [PMID: 19231968 DOI: 10.1089/ten.tea.2009.0294]

Lee HK, Shin YK, Jung J, Seo SY, Baek SY, Park HT. Proteasome inhibition suppresses Schwann cell dedifferentiation in vitro and in vivo. Glia 2009; 57: 1825-1834 [PMID: 19455715 DOI: 10.1002/glia.20894]

Gordon T. The role of neurotrophic factors in nerve regeneration. Neurosurg Focus 2009; 26: E3 [PMID: 19228105 DOI: 10.3171/FOC/2009.26.2.E3]

Ruohonen S, Khadem M, Jagodic M, Taskinen HS, Olsson T, Rottay M. Cytokine responses during chronic denervation. J Neurolinflammation 2005; 2: 6 [PMID: 16287511 DOI: 10.1186/1744-8002-5-26]

Shamash S, Reichert F, Rothshenker S. The cytokine network of Wallerian degeneration: tumor necrosis factor-alpha, interleukin-1alphap, and interleukin-1beta. J Neurosci 2002; 22: 3652-3660 [PMID: 11943808 DOI: 10.1057/11443-000]

Gaudet AD, Popovich PG, Ramer MS. Wallerian degenera-
tion: gaining perspective on inflammatory events after peripheral nerve injury. J Neuroinflammation 2011; 8: 110 [PMID: 21878126 DOI: 10.1186/1742-2048-8-110]

119 Waller A. Experiments on the section of the glossopharyngeal and hypoglossal nerves of the frog, and observations of the alterations produced thereby in the structure of their primitive fibres. Phil Trans Act Soc London 1850; 140: 423-429

120 Dubovy P. Wallerian degeneration and peripheral nerve conditions for both axonal regeneration and neuropathic pain induction. Ann Anat 2011; 193: 267-275 [PMID: 21485249 DOI: 10.1016/j.aanat.2011.02.011]

121 Martinez AM, Ribiero LC. Ultrastructural localization of calcium in peripheral nerve fibres undergoing Wallerian degeneration: an oxalate-pyroantimonate and X-ray microanalysis study. J Submicrosc Cytol Pathol 1998; 30: 451-458 [PMID: 9723205]

122 Zhao Q, Wang J, Kim A, Liu Q, Watts R, Hoopfer E, Mitchison T, Luo L, He Z. Involvement of the ubiquitin-proteasome system in the early stages of wallerian degeneration. Neuron 2003; 39: 217-225 [PMID: 12873580 DOI: 10.1016/S0896-6273(03)00429-X]

123 Guettin AD, Zhang DP, Mak KS, Alberta JA, Kim HA. Microanatomy of axon/glia signaling during Wallerian degeneration. J Neurosci 2005; 25: 3478-3487 [PMID: 15800203 DOI: 10.1523/JNEUROSCI.3766-04.2005]

124 White FV, Toews AD, Goodrum JF, Novicki DL, Bouldin TW, Morell P. Lipid metabolism during early stages of Wallerian degeneration in the rat sciatic nerve. J Neurochem 1989; 52: 1085-1092 [PMID: 292690 DOI: 10.1111/j.1471-4159.1989.tb08151.x]

125 Murinson BB, Archer DR, Li Y, Griffin JW. Degeneration of myelinated efferent fibers prompts mitosis in Remak Schwann cells of uninjured C-fiber afferents. J Neurosci 2005; 25: 1179-1187 [PMID: 15689554 DOI: 10.1523/JNEUROSCI.1372-04.2005]

126 Griffith JW, Pan B, Bolley MA, Hoffman PN, Farah MH. Measuring nerve regeneration in the mouse. Exp Neurol 2010; 223: 60-71 [PMID: 20080884 DOI: 10.1016/j.expneurol.2009.12.033]

127 Gersh I, Bodian D. Some chemical mechanisms in chromatolysis. J Cell Comp Physiol 1943; 21: 253-279 [DOI: 10.1002/ jcp.103021005]

128 Lieberman AR. The axon reaction: a review of the principal features of perikaryal responses to axon injury. Int Rev Neurobiol 1971; 14: 49-124 [PMID: 4948561]

129 Deumens R, Bosskurt A, Meek MF, Marcus MA, Joosten EA, Weis J, Brock GA. Repairing injured peripheral nerves: Bridging the gap. Prog Neurobiol 2010; 92: 245-276 [PMID: 20950667 DOI: 10.1016/j.pneurobio.2010.10.002]

130 Oliveira JT, Almeida FM, Biancalana A, Baptista AF, Tomaz MA, Melo PA, Martinez AM. Mesenchymal stem cells in a polycaprolactone conduit enhance median-nerve regeneration, prevent decrease of creatine phosphokinase levels in muscle, and improve functional recovery in mice. Neuroscience 2010; 170: 1295-1303 [PMID: 20808664 DOI: 10.1016/j.neuroscience.2010.08.042]

131 Frattini F, Lopes FR, Almeida FM, Rodrigues RF, Boldrini LC, Tomaz MA, Baptista AF, Melo PA, Martinez AM. Mesenchymal stem cells in a polycaprolactone conduit promote sciatric nerve regeneration and sensory neuron survival after nerve injury. Tissue Eng Part A 2012; 18: 2030-2039 [PMID: 22646222 DOI: 10.1089/teng.TEA.2011.0406]

132 Dezawa M, Takahashi I, Esaki M, Takano M, Sawada H. Sciatric nerve regeneration in rats induced by transplantation of in vitro differentiated bone-marrow stromal cells. Eur J Neurosci 2001; 14: 1771-1776 [PMID: 11860471 DOI: 10.1046/j.0953-8166.2001.01814.x]

133 Pereira Lopes FR, Camargo de Moura Campos L, Dias Corrêa J, Balduino A, Lora S, Langone F, Boroejvic R, Blanco Martinez AM. Bone marrow stromal cells and resorbable collagen guidance tubes enhance sciatric nerve regeneration in mice. Exp Neurol 2006; 198: 457-468 [PMID: 16487971 DOI: 10.1016/j.expneurol.2005.12.019]

134 Ribeiro-Resende VT, Pimentel-Coelho PM, Mesentier-Louveiro LA, Mendez RM, MeloSilva JP, Cabral-da-Silva MC, de Mello FG, de Mello Reis RA, Mendez-Otero R. Trophic activity derived from bone marrow mononuclear cells increases peripheral nerve regeneration by acting on both neuronal and glial cell populations. Neuroscience 2009; 159: 540-549 [PMID: 19174184 DOI: 10.1016/j.neuroscience.2008.12.059]

135 Oliveira JT, Mostacada K, de Lima S, Martinez AM. Bone marrow mesenchymal stem cell transplantation for improving nerve regeneration. Int Rev Neurobiol 2013; 118: 59-77 [PMID: 24083431 DOI: 10.1016/B978-0-12-41049-0.00003-4]
Olivera JT, Almeida FM, Biancalana A, Baptista AF, Tomaz MA, Melo PA, Martinez AM. Mesenchymal stem cells in a polycaprolactone conduit enhance median-nerve regeneration, present decrease of creatine phosphokinase levels in muscle, and improve functional recovery in mice. *Neuroscience* 2010; 170: 1295-1303 [PMID: 20800664]

Zhaosha Z, Wang Y, Peng J, Ren Z, Zhan S, Liu Y, Zhao B, Zhao Q, Zhang L, Guo Q, Xu W, Lu S. Repair of nerve defect with acellular nerve graft supplemented by bone marrow stem cells in mice. *Microsurgery* 2011; 31: 388-394 [PMID: 21503972 DOI: 10.1002/micr.20882]

Marchioni S, Castiglione G, Turano E, Bissolotti G, Angiari S, Farinazzo A, Constantin G, Bedogni G, Bedogni A, Bonetti B. Human adipose-derived mesenchymal stem cells systemically injected promote peripheral nerve regeneration in the mouse model of sciatic crush. *Tissue Eng Part A* 2012; 18: 1264-1272 [PMID: 22352955 DOI: 10.1089/ten.TEA.2011.0491]

Cheng FC, Tai MH, Sheu ML, Chen CJ, Yang DY, Su HL, Ho SP, Lai SZ, Pan HC. Enhancement of regeneration with glia cell line-derived neurotrophic factor-transduced human amniotic fluid mesenchymal stem cells after sciatic nerve crush injury. *J Neurosurg* 2010; 112: 868-879 [PMID: 19817545 DOI: 10.3171/2009.8.JNS09850]

Yang Li, Chang KW, Chung KC. A systematic review of transfer nerve and nerve repair for the treatment of adult upper brachial plexus injury. *Neurosurgery* 2012; 71: 417-29; discussion 429 [PMID: 22811085 DOI: 10.1093/neuros/228578]

Jia H, Wang Y, Tong XJ, Liu GB, Li Q, Zhang LX, Sun XH. Sciatic nerve repair by acellular nerve xenografts implanted with BMSCs in rats xenograft combined with BMSCs. *Synapse* 2012; 66: 256-269 [PMID: 22127791 DOI: 10.1002/syn.21508]

Wang Y, Jia H, Li WY, Tong XJ, Liu GB, Kang SW. Synergistic effects of bone mesenchymal stem cells and chondroitinase ABC on nerve regeneration after acellular nerve allograft in rats. *Cell Mol Neurobiol* 2012; 32: 361-371 [PMID: 22905686 DOI: 10.1007/s10571-011-9764-4]

Satar B, Hidir Y, Serdar MA, Kucuktag Z, Ural AU, Avcu F, Safalı M, Oguztuzun S. Protein profiling of anastomosed facial nerve treated with mesenchymal stromal cells. *Cytoterapy* 2012; 14: 522-538 [PMID: 22685250 DOI: 10.3109/10652549.2011.651530]

Costa JJ, Ferreira Bento R, Salomone R, Azzi-Nogueira D, Zanatta DB, Paulino Costa M, da Silva CF, Strauss BE, Hadjigeorgiou M. Differentiated mesenchymal stem cells for sciatic nerve treatment. *J Neurosurg* 2012; 117: 2251-2264 [PMID: 21542668 DOI: 10.1093/ten.NEA.2011.01.013]

Ao Q, Fung CK, Tsai AY, Cai S, Zuo HC, Chan YS, Shum DK. The regeneration of transected sciatic nerves of adult rats using chorion vesicle-derived mesenchymal stem cells seeded with bone marrow stem-cell-derived Schwann cells. *Biomaterials* 2011; 32: 787-796 [PMID: 20958852 DOI: 10.1016/j.biomaterials.2010.9.046]

Yang Y, Yuan X, Ding F, Yao D, Gu Y, Liu J, Gu X. Repair of rat sciatic nerve gap by a silk fibroin-based scaffold added with bone marrow mesenchymal stem cells. *Tissue Eng Part A* 2011; 17: 2251-2264 [PMID: 21542668 DOI: 10.1089/ten.NEA.2011.01.013]

Liao IC, Wan H, Qi S, Cui C, Patel P, Sun W, Xu H. Preclinical evaluations of acellular biological conduits for peripheral nerve regeneration. *J Tissue Eng* 2013; 4: 2014731413481036

Zheng L, Cui HF. Use of chitosan conduit combined with bone marrow mesenchymal stem cells for promoting peripheral nerve regeneration. *J Mater Sci Mater Med* 2010; 21: 1713-1720 [PMID: 20744139 DOI: 10.1007/s10585-010-4005-y]

Ladak A, Olson J, Tredget EE, Gordon T. Differentiation of mesenchymal stem cells to support peripheral nerve regeneration in a rat model. *Exp Neurol* 2011; 228: 242-252 [PMID: 21281630 DOI: 10.1016/j.jengene.2011.06.033]

Zheng L, Cui HF. Enhancement of nerve regeneration along a chitosan conduit combined with bone marrow mesenchymal stem cells. *J Mater Sci Mater Med* 2012; 23: 2291-2302 [PMID: 22661248 DOI: 10.1007/s10856-012-4694-3]

Nijhuis TH, Bodaar CW, van Noort JW, Walbeeht EM, Siemionow M, Madajka M, Cwykkel J, Blok JH, Hovius SE. Natural conduits for bridging a 15-mm nerve defect: comparison of the vein supported by muscle and bone marrow stem cells with a nerve autograft. *J Plast Reconstr Aesthet Surg* 2013; 66: 251-259 [PMID: 23063384 DOI: 10.1016/j.bjps.2012.09.011]

Zhao Z, Wang Y, Peng J, Ren Z, Zhang L, Guo Q, Xu W, Lu S. Improvement in nerve regeneration through a decellularized nerve graft by supplementation with bone marrow stromal cells in fibrin. *Cell Transplant* 2013; 22: 97-110 [PMID: 23128095 DOI: 10.7776/389719x2588485]

You D, Jang MJ, Lee J, Jeong IC, Kim HS, Moon KH, Suh N, Kim CS. Periprosthetic implantation of human bone marrow-derived mesenchymal stem cells potentiates recovery of erectile function by intracavernosal injection in a rat model of cavernous nerve injury. *Urology* 2013; 81: 104-110 [PMID: 23122545 DOI: 10.1016/j.urology.2012.08.046]

Wang X, Luo E, Li Y, Hu J. Schwann-like mesenchymal stem cells within vein graft facilitate nerve regeneration and remyelination. *Brain Res* 2011; 1383: 71-90 [PMID: 21295556 DOI: 10.1016/j.brainres.2011.01.098]

Shen J, Duan XH, Cheng LN, Zhong XM, Guo RM, Zhang F, Zhou CP, Liang BL. In vivo MR imaging tracking of transplanted mesenchymal stem cells in a rabbit model of acute peripheral nerve traction injury. *J Magn Reson Imaging* 2010; 31: 20622 [PMID: 23528562 DOI: 10.1089/1741-2560-10/2/0260 22]

Matsuse D, Kitada M, Kohama M, Nishikawa K, Kanemokishima H, Wakao S, Fujiyoshi Y, Heike T, Nakahata T, Akutsu H, Umezawa A, Nakagawara H, Higashi K, Ichikawa N. Human umbilical cord-derived mesenchymal stromal cells differentiate into functional Schwann cells that sustain peripheral nerve regeneration. *J Neuroplast Exp Neurol* 2010; 69: 973-985 [PMID: 20720501 DOI: 10.1088/0963-6897/2011/01/007]

Gärtner A, Pereira T, Alves MG, Armada-da-Silva PA, Amorim I, Gomes R, Ribeiro J, França ML, Lopes C, Carvalho RA, Socorro S, Oliveira PF, Porto B, Sousa R, Bombaci A, Ronchi G, Fregonan F, Varejoio AS, Luis AL, Geuna S, Mauricio AC. Use of poly(L-Lactide-c-caprolactone) membranes and mesenchymal stem cells from the Wharton’s jelly of the umbilical cord for promoting nerve regeneration in axonotmesis: in vitro and in vivo analysis. *Differentiation* 2012; 84: 355-365 [PMID: 23142731 DOI: 10.1016/j.diff.2012.10.001]

Zheng L, Cui HF. Use of chitosan conduit combined with bone marrow mesenchymal stem cells for promoting peripheral nerve regeneration. *J Mater Sci Mater Med* 2010; 21: 1713-1720 [PMID: 20744139 DOI: 10.1007/s10585-010-4005-y]
Martinez AMB et al. Mesenchymal stem cells for neurotrauma treatment

32: 1076-1085 [PMID: 21031511 DOI: 10.1002/jmri.22353]
173 Duan XH, Cheng LN, Zhang F, Liu J, Guo RM, Zhong XM, Wen XH, Shen J. In vivo MRI monitoring nerve regeneration of acute peripheral nerve traction injury following mesenchymal stem cell transplantation. *Eur J Radiol* 2012; 81: 2154-2160 [PMID: 21726973 DOI: 10.1016/j.ejrad.2011.06.050]
174 Cho HH, Jang S, Lee SC, Jeong HS, Park JS, Han JY, Lee KH, Cho YB. Effect of neural-induced mesenchymal stem cells and platelet-rich plasma on facial nerve regeneration in an acute nerve injury model. *Laryngoscope* 2010; 120: 907-913 [PMID: 20422684 DOI: 10.1002/lary.20860]
175 Ding F, Wu J, Yang Y, Hu W, Zhu Q, Tang X, Liu J, Gu X. Use of tissue-engineered nerve grafts consisting of a chitosan/poly(lactic-co-glycolic acid)-based scaffold included with bone marrow mesenchymal cells for bridging 50-mm dog sciatic nerve gaps. *Tissue Eng Part A* 2010; 16: 3779-3790 [PMID: 20666610 DOI: 10.1089/ten.TEA.2010.0299]
176 Ghoreishian M, Rezaei M, Beni BH, Javanmard SH, Attab BM, Zalzali H. Facial nerve repair with Gore-Tex tube and adipose-derived stem cells: an animal study in dogs. *J Oral Maxillofac Surg* 2013; 71: 577-587 [PMID: 22868036 DOI: 10.1016/j.joms.2012.05.025]
177 Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006; 8: 315-317 [PMID: 16923606 DOI: 10.1080/14653240600855905]

P- Reviewers: Kita K, Zocchi E  S- Editor: Song XX  L- Editor: A  E- Editor: Zhang DN
